IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (1217)	8/18/1997 11:38:00 PM
From: Pseudo Biologist	of 1762

I do not have additional information on clinical data. The other "immuno" company with anti-CD20 may be Immunomedics: biz.yahoo.com (the original MAb is called LL2) I think the biology of CD20 is quite another unexplored (by me?) issue. For most purposes people think of these things as just "markers" or targets to which you shoot the "magic" bullet. On apoptosis, I think you are right; it may be generic to at least some anti-CD20's. Kaminski sees an effect in Bexxar therapy even at the imaging/pre-targeting stages (i.e. with little or no radioactive load) as one would expect, now that we know C2B8 works. Keep the worries coming.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next